Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5738713 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL5739237 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL5739981 | 0.95 | SMN1; SMN2 (0.64) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL5739863 | 0.94 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL5739138 | 0.89 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL11600633 | 0.84 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL4239583 | 0.79 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL25023538 | 0.77 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL30306920 | 0.77 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL4248531 | 0.77 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244670-B1 | HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USING SAME | MGI GP INC (US) | 2006-03-08 | — | — | EP | claimed |
| EP-1244670-A1 | HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USING SAME | GPI NIL Holdings, Inc. (US) | 2002-10-02 | — | — | EP | claimed |
| US-20020058685-A1 | Hydantoin derivative compounds, pharmace utical compositions, and methods of using same | GLIAMED, INC. | 2002-05-16 | — | — | US | claimed |
| WO-2001046195-A1 | HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USING SAME | GPI NIL HOLDINGS, INC. (US) | 2001-06-28 | — | — | WO | claimed |
| EP-1244670-B1 | HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USING SAME | MGI GP INC (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6974823-B2 | Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same | GPI NIL HOLDINDGS, INC. (US) | 2005-12-13 | — | — | US | disclosed |
| US-20030203890-A1 | Method for treating nerve injury caused as a result of surgery | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-10-30 | — | — | US | disclosed |
| US-20020058685-A1 | Hydantoin derivative compounds, pharmace utical compositions, and methods of using same | GLIAMED, INC. | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203890-A1 | Method for treating nerve injury caused as a result of surgery | NGF, BDNF, GAP43 | SMN1; SMN2 154/4885ALDH1A1 824/4885KDM4E 3292/4885 |
| US-20020058685-A1 | Hydantoin derivative compounds, pharmace utical compositions, and methods of using same | HNMT, HAAO, HTR3E | SMN1; SMN2 2299/4885ALDH1A1 1066/4885KDM4E 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.